Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06930755 as recruiting, last updated 2026-05-28. Enrolment is 24 planned participants, an estimate. Interventions: NMS-03305293, Topotecan. Primary measures include Number of Participants with Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares NMS-03305293, PARP.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Shares PARP, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/